Literature DB >> 30459116

Comparison of Cognitive Intervention Strategies for Older Adults With Mild to Moderate Alzheimer's Disease: A Bayesian Meta-analytic Review.

Jing-Hong Liang1, Jia-Yu Li1, Rui-Xia Jia1, Ying-Quan Wang1, Rong-Kun Wu1, Hong-Bo Zhang1, Lei Hang1, Yong Xu2, Chen-Wei Pan3.   

Abstract

OBJECTIVES: We aimed to identify the best form of cognitive therapy among 3 main cognitive interventions of Alzheimer's disease (AD) including cognitive training (CT), cognitive stimulation (CS), and cognitive rehabilitation (CR).
DESIGN: Systematic review and Bayesian network meta-analysis. SETTING AND PARTICIPANTS: An exhaustive literature search was conducted based on PubMed, Embase, the Cochrane Central Register of Controlled Trials, PsycINFO, the China National Knowledge Infrastructure database, the Chinese Biomedical Literature database, the Wan Fang database, and Web of Science and other database and randomized controlled trials were identified from their inception to May 1, 2018. Older adult participants diagnosed with AD were recruited. MEASURES: We conducted a Bayesian network meta-analysis (NMA) to rank the included treatments. Cognitive functions were measured based on the Mini-Mental State Examination (MMSE). A series of analyses and assessments, such as the Pairwise meta-analysis and the risk of bias, were performed concurrently.
RESULTS: Only 22 studies were included in our analysis based on a series of rigorous screenings, which comprised 1368 participants. No obvious heterogeneities were found in NMA (I2 = 32.7%, P = .07) after the data were pooled. The mean difference (MD) of CT [MD = 2.1, confidence interval [CI]: 1.0, 3.2), CS (MD = 0.92, CI: -0.20, 2.0), and CR (MD = 2.0, CI: 0.73, 3.4) showed that CT and CR could significantly improve cognitive function as measured by MMSE in the treatment group whereas the CS was less effective. CT had the highest probability among the 3 cognitive interventions [the surface under the cumulative ranking curve (SUCRA) = 84.7%], followed by CR (SUCRA = 50.0%) and CS (SUCRA = 47.4%). CONCLUSIONS/RELEVANCE: Our study indicated that the CT might be the best method for improving the cognitive function of AD patients. The findings from our study may be useful for policy makers and service commissioners when they make choices among different alternatives. Published by Elsevier Inc.

Entities:  

Keywords:  Alzheimer's disease; Bayesian network meta-analysis; cognitive intervention strategies

Mesh:

Year:  2018        PMID: 30459116     DOI: 10.1016/j.jamda.2018.09.017

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  6 in total

1.  A 4-Item Case-Finding Tool to Detect Dementia in Older Persons.

Authors:  Tau Ming Liew
Journal:  J Am Med Dir Assoc       Date:  2019-08-07       Impact factor: 4.669

2.  Developing a Brief Neuropsychological Battery for Early Diagnosis of Cognitive Impairment.

Authors:  Tau Ming Liew
Journal:  J Am Med Dir Assoc       Date:  2019-04-13       Impact factor: 4.669

3.  The Optimal Short Version of Montreal Cognitive Assessment in Diagnosing Mild Cognitive Impairment and Dementia.

Authors:  Tau Ming Liew
Journal:  J Am Med Dir Assoc       Date:  2019-03-23       Impact factor: 4.669

Review 4.  A Conceptual View of Cognitive Intervention in Older Adults With and Without Cognitive Decline-A Systemic Review.

Authors:  Liliana Mendes; Joana Oliveira; Fernando Barbosa; Miguel Castelo-Branco
Journal:  Front Aging       Date:  2022-03-24

Review 5.  The Effect of Cognitive Intervention on Cognitive Function in Older Adults With Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Authors:  Yun-Yun Wang; Liang Yang; Jing Zhang; Xian-Tao Zeng; Yang Wang; Ying-Hui Jin
Journal:  Neuropsychol Rev       Date:  2021-04-24       Impact factor: 7.444

6.  Cognitive training for elderly patients with early Alzheimer's disease in the Qinghai-Tibet Plateau: A pilot study.

Authors:  Xiao-Hong Wang; Ming-Qin Luo
Journal:  World J Clin Cases       Date:  2022-08-16       Impact factor: 1.534

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.